Ardelyx, Inc. (ARDX)
After hours:
| Previous Close | 8.06 |
| Open | 8.05 |
| Bid | 7.76 x 2100 |
| Ask | 7.81 x 1000 |
| Day's Range | 7.59 - 8.11 |
| 52 Week Range | 3.16 - 10.13 |
| Volume | |
| Avg. Volume | 6,048,869 |
| Market Cap | 1.818B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.95 |
GlobeNewswireArdelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to
Insider MonkeyArdelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript May 2, 2024 Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Ardelyx […]
Simply Wall St.Ardelyx First Quarter 2024 Earnings: Beats Expectations
Ardelyx ( NASDAQ:ARDX ) First Quarter 2024 Results Key Financial Results Revenue: US$46.0m (up 305% from 1Q 2023). Net...
